Cardiovascular mortality trends in non-Hodgkin’s lymphoma: a population-based cohort study

References

• Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2002. Available at: http://seer.cancer.gov/csr/1975_2000 . Accessed June 1, 2003.
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar;136(5):E359–86. PubMed PMID: 25220842; eng. DOI:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. Sep 2016. PubMed PMID: 27618563; eng. DOI: 10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May;127(20):2375–2390. PubMed PMID: 26980727; PubMed Central PMCID: PMCPMC4874220. eng. DOI:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7–30. PubMed PMID: 26742998; eng. DOI:10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Dobrinja C, Trevisan G, Liguori G. Primary bilateral adrenal non-Hodgkin’s Burkitt-like lymphoma: a rare cause of primary adrenal insufficiency. Case report and literature review. Tumori. 2007 Nov-Dec;93(6):625–630. PubMed PMID: 18338503; eng.
   PubMed Web of Science ®Google Scholar
• Greer S, Haynes JW Non-Hodgkin’s lymphoma. eMedRef (MU). 2012.
   Google Scholar
• Shankland KR, Armitage JO, Hancock BW. Non-hodgkin lymphoma. The Lancet. 2012;380(9844):848–857.
   PubMed Web of Science ®Google Scholar
• Boffetta PI. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncology. 2011;22(suppl_4):iv27–iv31.
   Web of Science ®Google Scholar
• Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin’s disease. JNCI. 1993;85(1):25–31.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. New Engl J Med. 1996;334(12):745–751.
   PubMed Web of Science ®Google Scholar
• Haddy TB, Adde MA, McCalla J, et al. Late effects in long-term survivors of high-grade non-Hodgkin’s lymphomas. J Clin Oncol. 1998;16(6):2070–2079.
   PubMed Web of Science ®Google Scholar
• André M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103(4):1222–1228.
   PubMed Web of Science ®Google Scholar
• Avilés A, Díaz-Maqueo JC, García EL, et al. Late lethal events in patients with diffuse large B cell lymphoma: a review of 714 patients treated in a single centre. Leuk Lymphoma. 2001;42(4):631–637.
   PubMed Web of Science ®Google Scholar
• Moser EC, Noordijk EM, Carde P, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clinical Lymphoma Myeloma. 2005;6(2):122–130.
   PubMedGoogle Scholar
• Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270(16):1949–1955.
   PubMed Web of Science ®Google Scholar
• Avilés A, Neri N, Nambo MJ, et al. Late cardiac toxicity secondary to treatment in Hodgkin’s disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma. 2005;46(7):1023–1028.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998 Jul 02;339(1):21–26. PubMed PMID: 9647875; eng. DOI:10.1056/nejm199807023390104
   PubMed Web of Science ®Google Scholar
• Avilés A, Delgado S, Fernández R, et al. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol. 2002;68(3):144–149.
   PubMed Web of Science ®Google Scholar
• Wilder RB, Rodriguez MA, Tucker SL, et al. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncology* Biology* Phys. 2001;50(3):743–749.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. New Engl J Med. 2004;350(13):1287–1295.
   PubMed Web of Science ®Google Scholar
• Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005 Aug;6(8):557–565. PubMed PMID: 16054566; eng. DOI:10.1016/s1470-2045(05)70251-5
   PubMed Web of Science ®Google Scholar
• Islam KM, Jiang X, Anggondowati T, et al. Comorbidity and survival in lung cancer patients. Cancer Epidemiol Prev Biomarkers. 2015;24(7):1079–1085.
   PubMed Web of Science ®Google Scholar
• Jeong SS, Choi PJ, Yi JH, et al. Impact of lifestyle diseases on postoperative complications and survival in elderly patients with stage I non-small cell lung cancer. Korean J Thorac Cardiovasc Surg. 2017 Apr;50(2):86–93. PubMed PMID: 28382266; PubMed Central PMCID: PMCPMC5380200. eng. DOI:10.5090/kjtcs.2017.50.2.86
   PubMedGoogle Scholar
• Aarts MJ, Aerts JG, van den Borne BE, et al. Comorbidity in patients with small-cell lung cancer: trends and prognostic impact. Clinical Lung Cancer. 2015 Jul;16(4):282–291. PubMed PMID: 25572007; eng. DOI:10.1016/j.cllc.2014.12.003
   PubMed Web of Science ®Google Scholar
• Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer in Southeast Asia: a prospective cohort study. Sci Rep. 2017 May 02;7(1):1365. PubMed PMID: 28465587; PubMed Central PMCID: PMCPMC5430976. eng. DOI:10.1038/s41598-017-01540-7
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. New England J Med. 1993;328(14):1002–1006. PubMed PMID: 7680764. DOI:10.1056/nejm199304083281404
   PubMed Web of Science ®Google Scholar
• Law LY, Horning SJ, Wong RM, et al. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006 Jul;12(7):703–711. PubMed PMID: 16785059; eng. DOI:10.1016/j.bbmt.2006.02.009
   PubMed Web of Science ®Google Scholar
• Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Jul;14(7):840–846. PubMed PMID: 18541205; eng. DOI:10.1016/j.bbmt.2008.05.002
   PubMed Web of Science ®Google Scholar
• Nademanee A, Molina A, Dagis A, et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin’s lymphoma. Clinical Lymphoma. 2000 Jun;1(1):46–54. PubMed PMID: 11707813; eng.
   PubMedGoogle Scholar
• Schmitt CJ, Dietrich S, Ho AD, et al. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin’s lymphoma patients with cardiac risk factors. Ann Hematol. 2012 Mar;91(3):391–397. PubMed PMID: 21850390; eng. DOI:10.1007/s00277-011-1308-y
   PubMed Web of Science ®Google Scholar
• Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005 Nov;46(11):1575–1579. PubMed PMID: 16236612; eng. DOI:10.1080/10428190500235884
   PubMed Web of Science ®Google Scholar
• SEER datasets. [cited 2017 Jan 16]. Available from: https://seer.cancer.gov/data/citation.html
   Google Scholar
• Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010 Nov;116(20):e90–8. PubMed PMID: 20699439; PubMed Central PMCID: PMCPMC2993636. eng. DOI:10.1182/blood-2010-06-289561
   PubMed Web of Science ®Google Scholar
• Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the pathology working group of the international lymphoma epidemiology consortium (InterLymph). Blood. 2007 Jul;110(2):695–708. PubMed PMID: 17389762; PubMed Central PMCID: PMCPMC1924473. eng. DOI:10.1182/blood-2006-11-051672
   PubMed Web of Science ®Google Scholar
• Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003 Feb;14(2):277–281. PubMed PMID: 12562656; eng.
   PubMed Web of Science ®Google Scholar
• Somers R, Carde P, Thomas J, et al. EORTC study of non-Hodgkin’s lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncology. 1994;5(Suppl 2):85–89. PubMed PMID: 7515651; eng.
   PubMed Web of Science ®Google Scholar
• Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clinical Oncology. 2008 Jul 01;26(19):3159–3165. PubMed PMID: 18591554; eng. DOI:10.1200/jco.2007.14.1242
   PubMed Web of Science ®Google Scholar
• Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984 Apr;32(4):269–273. PubMed PMID: 6368652; eng.
   PubMed Web of Science ®Google Scholar
• Vose JM, Armitage J, Weisenburger D, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1988;6(12):1838–1844.
   PubMed Web of Science ®Google Scholar
• Ayala E, Figueroa J, Perkins J, et al. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):335–340. PubMed PMID: 25659459; eng. DOI:10.1016/j.clml.2014.12.016
   PubMed Web of Science ®Google Scholar
• Maartense E, Kluin-Nelemans HC, le Cessie S, et al. Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. Cancer. 2000 Dec 15;89(12):2667–2676. PubMed PMID: 11135230; eng.
   PubMed Web of Science ®Google Scholar
• Bai LY, Yang MH, Chiou TJ, et al. Non‐Hodgkin lymphoma in elderly patients. Cancer. 2003;98(6):1188–1195.
   PubMed Web of Science ®Google Scholar
• Crozier JA, Sher T, Yang D, et al. Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review. Clin Lymphoma Myeloma Leuk. 2015 Oct;15(10):578–585. PubMed PMID: 26198444; eng. DOI:10.1016/j.clml.2015.06.005
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008 Mar 10;168(5):469–476. PubMed PMID: 18332290; eng. DOI:10.1001/archinternmed.2007.125
   PubMedGoogle Scholar
• Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011 Nov;124(19):2145–2154. PubMed PMID: 22064958; PubMed Central PMCID: PMCPMC3362050. eng. DOI:10.1161/CIRCULATIONAHA.110.968792
   PubMed Web of Science ®Google Scholar
• Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007 Apr;62(1):43–52. PubMed PMID: 17287129; eng.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Müller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014 Jan;123(5):640–646. PubMed PMID: 24297867; eng. DOI:10.1182/blood-2013-07-517037
   PubMed Web of Science ®Google Scholar
• Al-Kindi SG, Abu-Zeinah GF, Kim CH, et al. Trends and disparities in cardiovascular mortality among survivors of Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):748–752. PubMed PMID: 26324747; eng.
   PubMed Web of Science ®Google Scholar
• Ross R, Dworsky R, Paganini-Hill A, et al. Non-Hodgkin’s lymphomas in never married men in Los Angeles. Br J Cancer. 1985;52(5):785.
   PubMed Web of Science ®Google Scholar
• Aizer AA, Chen M-H, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013 Sep 23;31(31):3869–3876. PubMed PMID: PMC4878087. DOI:10.1200/JCO.2013.49.6489
   PubMed Web of Science ®Google Scholar
• Bush RS, Gospodarowicz M, Sturgeon J, et al. Radiation therapy of localized non-Hodgkin’s lymphoma. Cancer Treat Rep. 1977;61.
   PubMedGoogle Scholar
• Zimmermann M, Oehler C, Mey U, et al. Radiotherapy for Non-Hodgkin’s lymphoma: still standard practice and not an outdated treatment option. Radiat Oncol. 2016 Aug 30;11(1):110. DOI:10.1186/s13014-016-0690-y.
   PubMed Web of Science ®Google Scholar
• Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma–results of the prospective German Multicenter Study GIT NHL 01/92. J Clinical Oncology. 2001 Sep 15;19(18):3874–3883. PubMed PMID: 11559725; eng. DOI:10.1200/jco.2001.19.18.3874
   PubMed Web of Science ®Google Scholar
• Kim SJ, Choi CW, Mun YC, et al. Multicenter retrospective analysis of 581 patients with primary intestinal non-Hodgkin lymphoma from the consortium for improving survival of lymphoma (CISL). BMC Cancer. 2011 Jul 29;11:321. PubMed PMID: 21798075; PubMed Central PMCID: PMCPMC3160411. eng. DOI:10.1186/1471-2407-11-321
   PubMed Web of Science ®Google Scholar
• Gospodarowicz MK, Bush R, Brown J, et al. Curability of gastrointestinal lymphoma with combined surgery and radiation. Int J Radiat Oncology* Biology* Phys. 1983;9(1):3–9.
   PubMed Web of Science ®Google Scholar
• Fleming ID, Mitchell S, Dilawari RA. The role of surgery in the management of gastric lymphoma. Cancer. 1982;49(6):1135–1141.
   PubMed Web of Science ®Google Scholar
• Paulson S, Sheehan R, Stone M, et al. Large cell lymphomas of the stomach: improved prognosis with complete resection of all intrinsic gastrointestinal disease. J Clin Oncol. 1983;1(4):263–269.
   PubMed Web of Science ®Google Scholar
• Herrera A, Solal-Celigny P, Bernard J High-risk primary lymphomas of the digestive tract: therapeutic results and study of prognostic factors. Non-Hodgkin’s Lymphomas: new Techniques and Treatments: Karger Publishers; 1985. p. 206–209.
   Google Scholar
• Dragosics B, Bauer P, Radaszkiewicz T. Primary gastrointestinal non‐Hodgkin’s lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer. 1985;55(5):1060–1073.
   PubMed Web of Science ®Google Scholar
• Rosenfelt F, Rosenberg SA. Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions the stanford experience. Cancer. 1980;45(8):2188–2193.
   PubMed Web of Science ®Google Scholar
• Ampil F. Primary gastrointestinal lymphoma. Oncology. 1987;44(4):214–218.
   PubMed Web of Science ®Google Scholar
• Economopoulos T, Alexopoulos C, Stathakis N, et al. Primary gastric lymphoma–the experience of a general hospital. Br J Cancer. 1985;52(3):391.
   PubMed Web of Science ®Google Scholar
• Sheridan WP, Medley G, Brodie GN. Non-Hodgkin’s lymphoma of the stomach: a prospective pilot study of surgery plus chemotherapy in early and advanced disease. J Clin Oncol. 1985;3(4):495–500.
   PubMed Web of Science ®Google Scholar
• Liang R, Todd D, Chan T, et al. Gastrointestinal lymphoma in Chinese: a retrospective analysis. Hematol Oncol. 1987;5(2):115–126.
   PubMed Web of Science ®Google Scholar
• Steward WP, Harris M, Wagstaff J, et al. A prospective study of the treatment of high-grade histology non-Hodgkin’s lymphoma involving the gastrointestinal tract. Eur J Cancer Clin Oncol. 1985;21(10):1195–1200.
   PubMedGoogle Scholar
• List AF, Greer J, Cousar J, et al. Non-Hodgkin’s lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J Clin Oncol. 1988;6(7):1125–1133.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Evans W, Kutas G, et al. Chemotherapy following surgery for stages IE and IIE non-Hodgkin’s lymphoma of the gastrointestinal tract. J Clin Oncol. 1988;6(2):253–260.
   PubMed Web of Science ®Google Scholar
• Janus C, Edwards B, Sariban E, et al. Surgical resection and limited chemotherapy for abdominal undifferentiated lymphomas. Cancer Treat Rep. 1984;68(4):599–605.
   PubMedGoogle Scholar
• Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006 Apr 01;107(7):2912–2919. PubMed PMID: 16339404; eng. DOI:10.1182/blood-2005-08-3392
   PubMed Web of Science ®Google Scholar
• Fox K, Cowie M, Wood D, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22(3):228–236.
   PubMed Web of Science ®Google Scholar
• Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125(1):47–58.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97(11):2869–2879.
   PubMed Web of Science ®Google Scholar
• Lopez-Messa JB, Andres-de Llano JM, Lopez-Fernandez L, et al. Trends in hospitalization and mortality rates due to acute cardiovascular disease in Castile and Leon, 2001 to 2015. Revista espanola de cardiologia (English Ed). 2017 Jul 31 PubMed PMID: 28774633; eng spa. DOI:10.1016/j.rec.2017.04.033
   Web of Science ®Google Scholar
• Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132(17):1667–1678.
   PubMed Web of Science ®Google Scholar
• Dégano IR, Elosua R, Marrugat J. Epidemiología del síndrome coronario agudo en España: estimación del número de casos y la tendencia de 2005 a 2049. Rev Esp Cardiol. 2013;66(6):472–481.
   PubMed Web of Science ®Google Scholar
• Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer. 1983 Jul;52(1):51–60. PubMed PMID: 6850545; eng.
   PubMed Web of Science ®Google Scholar
• Lotrionte M, Palazzoni G, Abbate A, et al. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study. Int J Cardiol. 2013 Aug;167(3):1055–1057. PubMed PMID: 23174173; eng. DOI:10.1016/j.ijcard.2012.10.079
   PubMed Web of Science ®Google Scholar
• Rühl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001 Dec;51(5):1209–1218. PubMed PMID: 11728679; eng.
   PubMed Web of Science ®Google Scholar
• Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013 Jun;61(23):2355–2362. PubMed PMID: 23583763; eng. DOI:10.1016/j.jacc.2013.02.072
   PubMed Web of Science ®Google Scholar